Four out of five cancer therapies tested in phase III trials do not achieve clinically-meaningful benefit in prolonging survival

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A study published in the Journal of the National Comprehensive Cancer Network found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login